{"prompt": "['20', 'MC1488 WEE1', 'MCCC', 'relapsed or refractory AML (> 18 years)', 'any MDS (> 18 years) having failed or been intolerant to prior', 'hypomethylating agent (HMA) treatment.', 'Failure is defined as any disease progression while on HMA,', 'relapse after HMA treatment or no response after 4 cycles of 5-', 'Azacitidine or decitabine', 'Patients with isolated 5q-/5q- syndrome must have failed, not', 'tolerated, or progressed on lenalidomide in addition to having', 'failed or been intolerant to HMA treatment.', 'Note: Patients with CMML and MDS/MPN overlap are allowed if', 'meeting other study eligibility criteria.', 'NOTE: For all patient groups, therapy as part of a plan as a bridge to transplant is', 'allowed.', '3.13', 'The following laboratory values obtained 7 days prior to registration.', \"Total bilirubin VI 1.5 mg/dL (except Gilbert's syndrome or known hemolysis\", 'or leukemic infiltration)', 'AST (SGOT) and ALT (SGPT) VI 2.5 X Upper Limit normal (ULN) or < 5 X', 'ULN if organ involvement', 'Alkaline Phosphatase < 5 X ULN', 'Serum creatinine VI 2 X ULN or 24 hour Cr clearance >30ml/min', '3.14', 'ECOG Performance Status (PS) 0, 1 or 2 (Appendix I).', '3.15', 'Ability to provide informed written consent and be able to adhere to the study', 'visit schedule and other protocol requirements.', '3.16', 'Willing to return to enrolling institution for follow-up (during the Active', 'Monitoring Phase of the study).', '3.17', 'Willing to provide blood and bone marrow aspirate samples for correlative', 'research purposes', '3.18', 'Negative serum pregnancy test done <7 days prior to registration, for women of', 'childbearing potential only.', '3.19a', 'Men and women must be willing to use appropriate contraception throughout', 'study and for 6 months after (please refer to Appendix IX for details).', '3.19b', 'Male patients who are sexually active with a female partner of childbearing', 'potential must be either surgically sterilized or agree to use barrier contraception', '(ie, condoms) for the duration of study participation, and for 90 days after the', 'final dose of study drug; cessation of birth control after this point should be', 'discussed with a responsible physician.', '3.19c Patients who have undergone stem cell transplantation (SCT), autologous or', 'allogeneic, are eligible provided that they are > 60 days from stem cell infusion,']['21', 'MC1488 WEE1', 'MCCC', 'have GVHD VI grade 1 and are off immunosuppressive agents for > 28 days at', 'time of registration.', '3.2', 'Exclusion Criteria', '3.21', 'Uncontrolled intercurrent illness including, but not limited to, active uncontrolled', 'infection, known positive for active infectious hepatitis, type A, B or C (past', 'infection allowed), or psychiatric illness/social situations that would limit', 'compliance with study requirements.', 'Note: ongoing infection controlled on antibiotics/antifungal/antiviral medications', 'are allowed.', '3.22', 'Any of the following prior therapies:', 'Cytotoxic Chemotherapy <14 days prior to registration', 'Immunotherapy <14 days prior to registration', 'Biologic therapy (i.e. antibody therapies) <14 days prior to registration', 'Radiation therapy <14 days prior to registration', \"Targeted therapies (i.e. kinase inhibitors, 7 days or 5 half-life's whichever\", 'is shorter)', 'For steroids or other non-cytotoxics given for blast count control, patient', 'must be off for > 24 hrs before starting therapy. NOTE: Hydroxyurea (HU) is', 'allowed for blast count control throughout study', 'Receiving any other investigational agent which would be considered as a', 'treatment for the primary neoplasm VI 14 days prior to registration', '3.23', 'Active uncontrolled CNS leukemia. NOTE: Positive (cyto)pathology is allowed', 'and patient can receive intrathecal chemotherapy', '3.24', 'Immunocompromised patients and patients known to be HIV positive and', 'currently receiving antiretroviral therapy. NOTE: Patients known to be HIV', 'positive, but without clinical evidence of an immunocompromised state, are', 'eligible for this trial.', '3.25', 'Any previous treatment with AZD1775 or allergic reactions to excipients of', 'AZD1775.', '3.26', 'Acute Promyelocytic Leukemia (APL, M3) unless failed regimens that included', 'tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT', 'candidates for stem cell transplantation.', '3.27', 'Major surgery VI 28 days prior to registration', '3.28', 'Clinically significant heart disease, including the following:', 'Active severe angina pectoris within 3 months prior to registration', 'Acute myocardial infarction within 3 months prior to registration', 'New York Heart Association classification IV cardiovascular disease or', 'symptomatic class III disease (Appendix III).']\n\n###\n\n", "completion": "END"}